Zelgor 250mg (Abiraterone)

Previous product
Zecyte 500mg (Abiraterone) A$1,197.08 A$2,968.86Price range: A$1,197.08 through A$2,968.86
Next product
Entehep 0.5mg (Entecavir) A$98.19 A$207.94Price range: A$98.19 through A$207.94

A$1,197.80 A$2,906.05Price range: A$1,197.80 through A$2,906.05

In Stock
In Stock

Zelgor 250mg (Abiraterone)

Pack SizePricePrice / UnitQuantityAdd To Cart
120 Tablet/sA$1,197.80A$9.98 / Tablet
240 Tablet/sA$1,985.50A$8.27 / Tablet
360 Tablet/sA$2,906.05A$8.07 / Tablet
Want to order in bulk / B2B price? Send Inquiry
×

Sorry!! Out of Stock

View All Abiraterone Products
Clear

Offer You Can't Resist

Free Shipping

Enjoy Free Shipping on Orders above AUD304 (USD199)
Estimate Shipping :
22 July - 29 July
42
SKU: N/A Categories: ,

What Our Customer Says

4.9
4.9 out of 5 stars (based on 215 reviews)

No Title

I am completely happy and satisfied after using Waklert 150 mg medicine, I will also prescribe this medicine to my friends and get the best result … !!

February 5, 2024
Last Updated on June 30, 2026
Description

Zelgor 250 mg (Abiraterone Acetate)

Brand Name: Zelgor
Active Ingredient: Abiraterone Acetate
Strength: 250 mg per tablet
Therapeutic Class: Antineoplastic Agent, Androgen Biosynthesis Inhibitor
Dosage Form: Oral tablet
Prescription Status: Prescription-only (Oncology medication)

Product Overview

Zelgor 250 mg contains Abiraterone Acetate, an effective androgen biosynthesis inhibitor employed in the treatment of prostate cancer. It targets specifically the CYP17 enzyme that plays a key role in the creation of androgens (male hormones) and not just in testes, but also in the adrenal glands, as well as prostate cancer tissue.

Through reducing androgen production, Zelgor assists in slowing the development of androgen-dependent prostate cancer cells. This makes it the most effective treatment for metastatic castration-resistant prostate cancer (mCRPC).

Composition

  • Each tablet contains:
    • Abiraterone Acetate – 250 mg
  • Inactive ingredients/excipients to ensure tablet stability and absorption.

Indications

Zelgor is indicated for:

  • Treatment of metastatic castration-resistant prostate cancer (mCRPC).
  • Utilize in conjunction with prednisone or prednisolone in accordance with standard cancer protocols.
  • Treatment of metastatic high-risk castration-sensitive prostate cancer (mCSPC) (as per local regulations approvals).

Mechanism of Action

Abiraterone acetate is a selective and irreversible inhibitor of CYP17A1 (17α-hydroxylase/C17, 20-lyase), an enzyme essential for androgen biosynthesis. Through inhibiting CYP17, it reduces testosterone production and other androgens within the adrenal glands, testes, and the tumor’s tissues, effectively denying prostate cancerous cells the hormones needed for their expansion and for their survival.

Dosage and Administration

Recommended Dosage:

  • The usual dosage that is recommended for Zelgor has a dose of 1000 mg (four 250 mg tablets) every day, orally on an empty stomach (at minimum 1 hour prior to or 2 hours following food).
  • It is recommended to take it together with prednisone or prednisolone (usually 5 mg two times daily) to reduce the mineralocorticoid overdose negative effects.

Administration Instructions:

  • Use tablets as they are; do not chew or crush them.
  • Take your medication with food and drink to reduce absorption, which could lead to toxic effects.
  • Be sure to follow the regimen strictly.
  • Monitoring of the liver’s functions regularly, as well as blood pressure is suggested.

Precautions and Warnings

  • Hepatotoxicity: Regularly monitor liver function tests or stop the medication if injuries to the liver occur.
  • Mineralocorticoid Excess: Hypertension can cause hypokalemia, hypertension, and the retention of fluids. Corticosteroids are essential for co-administration.
  • Cardiovascular Risk: Be cautious in patients who have an antecedent history of cardiovascular diseases.
  • Pregnancy: Not recommended for pregnant women or could get expecting or may become pregnant.
  • Drug Interactions: Do not take excessive CYP3A4 inhibitors or inducers because they could alter plasma abiraterone levels.
  • Adrenal Insufficiency: Patients should be watched closely for symptoms and signs.

Side Effects

Common side effects include:

  • Fatigue
  • Joint swelling or pain (arthralgia)
  • Edema (fluid retention)
  • Hypertension
  • Hot flashes
  • Elevated liver enzymes
  • Hypokalemia (low potassium levels)
  • Nausea and vomiting

Serious side effects:

  • Severe liver toxicity
  • Cardiac events (heart failure, arrhythmias)
  • Adrenal insufficiency symptoms
  • Severe allergic reactions (rare)

Contraindications

  • Hypersensitivity to abiraterone or any excipients.
  • Pregnancy and lactation.
  • Severe hepatic impairment.
  • Utilization in conjunction with stronger CYP3A4 inhibitors or inducers, without medical guidance.

Storage

  • Store at room temperature (20°C–25°C).
  • Guard against light and moisture.
  • Make sure that the area is safe for children.

Patient Counseling

  • Take Zelgor, and have an empty stomach. Avoid eating prior to or after taking the medication according to the directions.
  • Always take concomitant prednisone/prednisolone to prevent side effects.
  • Report any symptoms, such as excessive fatigue, jaundice, trouble breathing, or swelling, immediately.
  • Regularly check-ups on blood pressure and liver function.
  • Tell your doctor about the medications and supplements that you’re taking.

Summary

Zelgor 250 mg (Abiraterone Acetate) is a crucial medication for treating advanced prostate cancer that is advanced by attacking androgen-producing pathways. Utilizing it, along with corticosteroids, improves the longevity and quality of life for patients suffering from metastatic resistant prostate cancer. A careful adherence to dosage as well as monitoring and managing adverse effects, is crucial for the best results.

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Zelgor 250mg (Abiraterone)”

Your email address will not be published. Required fields are marked *

Are you human? Please solve:Captcha


Recently Viewed